KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Research & Development (2016 - 2025)

Gilead Sciences' Research & Development history spans 17 years, with the latest figure at $1.6 billion for Q4 2025.

  • For Q4 2025, Research & Development fell 3.47% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $5.8 billion, down 1.81%, while the annual FY2025 figure was $5.8 billion, 1.83% down from the prior year.
  • Research & Development reached $1.6 billion in Q4 2025 per GILD's latest filing, up from $1.3 billion in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.6 billion in Q4 2024 to a low of $1.1 billion in Q1 2021.
  • Average Research & Development over 5 years is $1.4 billion, with a median of $1.4 billion recorded in 2024.
  • Peak YoY movement for Research & Development: decreased 15.94% in 2021, then grew 27.68% in 2023.
  • A 5-year view of Research & Development shows it stood at $1.4 billion in 2021, then increased by 13.99% to $1.5 billion in 2022, then decreased by 9.04% to $1.4 billion in 2023, then increased by 16.55% to $1.6 billion in 2024, then decreased by 3.47% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for GILD's Research & Development are $1.6 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.5 billion (Q2 2025).